USA | Biotechnology Equity Research 2026 Outlook -- Top Ideas, Hidden Gems, M&A, & Key Catalysts Our outlook includes thoughts into 2026, including (in order by mkt cap) our top ideas (DNTH, TSHA, TNGX, TYRA, ORIC, SLDB), our underappreciated/ comeback names (RARE+MREO, BEAM, AUPH, KOD, NTLA, CMPX, KALV), major catalysts, M&A picks, and model updates (ARWR & KOD). **Slides inside** Early'26 pre-reports and guidances to watch: ALNY, CRSP (VRTX on Casgevy), RARE, TVTX, & BCRX pre-reported 4Q sales in early'Ja ...

智通财经APP获悉，杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标 的、被低估的潜力企业和潜在并购机会。该行指出，2026年生物科技领域将迎来多项关键临床试验数据 披露、新药审批及政策动态，细分赛道企业有望凭借技术突破与商业化进展实现价值重估。 杰富瑞基于市场催化剂的丰富程度和估值潜力，筛选出六家公司作为2026年的核心推荐： Dianthus Therapeutics(DNTH.US)，目标价66美元：主打药物claseprubart(一种补体C1s抑制剂)在多种神 经肌肉疾病中展现出潜力，包括慢性炎性脱髓鞘性多发性神经根神经病(CIDP)、全身型重症肌无力 (gMG)和多灶性运动神经病(MMN)，预估峰值收入达20亿美元。2026年，该公司将迎来CIDP三期临床 试验中期分析、gMG三期试验启动等多项关键节点。 Taysha Gene Therapies(TSHA.US)，目标价11美元：基因疗法TSHA-102用于治疗雷特综合征，市场潜力 巨大(预估峰值收入20亿美元)。其关键优势在于鞘内注射给药，安全性优于部分全身给药的基因疗法。 该核心产品的三期临床试验预计将在2026 ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 12 best multibagger stocks to buy heading into 2026. Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX) saw Canaccord analyst John Newman initiate coverage of the stock with a “Buy” rating and a $10 price target. The analyst attributed the bullish stance to positive data in the first quarter of 2026 from second-line biliary tract cancer studies. Newman sees tovecimig as ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Compass Therapeutics, Inc. (CMPX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Compass Therapeutics, Inc. is one of 946 individual stocks in the Medi ...

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan Virtual/Replay availability: The presentation will be archived on Compass’ Events page. Investors ...

Core Viewpoint - Compass Therapeutics, Inc. (CMPX) has shown a 13% gain over the past four weeks, with a mean price target of $12.62 indicating a potential upside of 134.1% from the current price of $5.39 [1] Price Targets and Analyst Estimates - The mean estimate consists of 13 short-term price targets with a standard deviation of $6.67, where the lowest estimate is $8.00 (48.4% increase) and the highest is $30.00 (456.6% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CMPX's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 1.6% over the past month, indicating a positive outlook [12] - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]

Core Insights - Compass is a monoclonal antibody discovery and development company focused on oncology, based in Boston [1] - The company currently has three drugs in clinical trials and a fourth drug set to enter the clinic [1] - 2026 is anticipated to be a significant year for the company with important updates expected [1] Drug Development Updates - The lead program, Tovecimig, is a DLL4xVEGF-A bispecific antibody, with readouts on secondary endpoints of progression-free survival and overall survival expected by the end of Q1 2026 [1] - In the second half of 2025, the company observed significant efficacy in a Phase I clinical trial of a PD-1, PD-L1 bispecific antibody, with three responses noted in the first 15 patients treated [2] - The company plans to expand cohorts for patients with triple-negative breast cancer and non-small cell lung cancer based on the observed efficacy [2]

Core Insights - The company has seen a significant stock price increase of 290% year-to-date, outperforming the XBI index which is up 30% [1] - The company is focused on monoclonal antibody discovery and development in oncology, with three drugs currently in clinical trials [2] Clinical Programs Overview - The most advanced program is a DLL4 VEGF-A bispecific antibody named tovecimig, which is in a randomized trial for patients with advanced biliary tract cancer [3] - The company reported achieving the primary endpoint in a randomized trial, with the overall response rate more than tripling compared to the control arm [3]

Summary of Compass Therapeutics FY Conference Call Company Overview - **Company**: Compass Therapeutics - **Industry**: Biotechnology, specifically focused on monoclonal antibody discovery and development in oncology - **Location**: Boston - **Current Pipeline**: Three drugs in clinical trials, with a fourth drug about to enter the clinic [2][3] Key Points and Arguments Upcoming Milestones - **Tevesemig**: A DLL4 VEGF-A bispecific antibody with a readout on secondary endpoints of progression-free survival (PFS) and overall survival (OS) expected by the end of Q1 2026 [2][3] - **PD-1, PD-L1 Bispecific Antibody**: Observed three responses in the first 15 patients treated in a phase 1 clinical trial, with cohort expansions planned for triple-negative breast cancer and non-small cell lung cancer [2][3][31] - **Fourth Drug**: A novel PD-1 VEGF-A bispecific antibody entering the clinic at the beginning of 2026 [3][4] Clinical Trial Insights - **Tevesemig Efficacy**: In a randomized study, the response rate in the combination arm (including Tevesemig) was more than triple that of the control arm, with a significant reduction in progressive disease incidence (42% in control vs. 16% in combination arm) [5][6][9] - **Survival Data**: Observations indicate fewer deaths than projected, suggesting improved overall survival [7][9][10] Market Opportunity - **Biliary Tract Cancer (BTC)**: Approximately 25,000 patients diagnosed annually in the U.S., with an estimated 15,000 patients eligible for second-line therapy, representing a multi-billion-dollar commercial opportunity [11][14] - **Duration of Therapy**: Current second-line chemotherapy duration is low single-digit months, while Tevesemig showed a median PFS of 9.4 months in a phase 2 study [12][14] Expansion Plans - **Frontline Studies**: Ongoing studies at MD Anderson to evaluate Tevesemig in combination with existing regimens, potentially increasing patient numbers by 50% [15][17] - **Additional Indications**: DLL4 expression is enriched in various malignancies, including hepatocellular, gastric, ovarian, renal cell, and colorectal cancers, indicating further expansion potential [17][18] Commercial Readiness - **Manufacturing Capability**: Compass has developed a robust commercial-ready manufacturing process for Tevesemig [20][21] - **Prescriber Awareness**: Initial pre-commercial work has begun, with plans for a full commercial launch preparation for a potential 2027 launch [20][21] Unique Mechanisms - **PD-1, PD-L1 Bispecific Antibody (8371)**: Utilizes a novel technology called StitchMabs, allowing for unique mechanisms of action, including T cell engagement and PD-1 cleavage [22][25] - **Differentiation**: The drug is positioned to have better PD-1 blockade compared to other molecules in development, with a focus on its unique mechanism [33][34] Other Important Insights - **Clinical Observations**: Notable responses in patients previously treated with other therapies, indicating potential for significant clinical impact [31] - **Future Indications**: Plans to explore additional indications for the PD-1 VEGF bispecific, including gastric cancer, hepatocellular, renal cell, and endometrial cancer [34] This summary encapsulates the critical insights and future directions for Compass Therapeutics as discussed in the conference call.

Summary of Compass Therapeutics Conference Call Company Overview - **Company**: Compass Therapeutics (NasdaqCM:CMPX) - **Industry**: Biotechnology, specifically focused on oncology and monoclonal antibody development - **Location**: Boston Key Clinical Programs Tevesemig (DLL4 VEGFA Bispecific Antibody) - **Current Status**: In a randomized trial for advanced biliary tract cancer - **Primary Endpoint Achievement**: Reported a tripling of the overall response rate compared to the control arm [4][10] - **Response Rate**: Achieved one of the highest response rates in second-line treatment for advanced biliary tract cancer [4] - **Disease Control Rate**: Significantly higher in the Tevesemig arm, suggesting potential improvements in progression-free survival (PFS) [5][10] - **Expected Data Release**: PFS and overall survival (OS) data anticipated by the end of Q1 2026 [8][11] - **Crossover Impact**: Approximately half of the control arm patients crossed over to receive Tevesemig, which may affect OS event accrual [16][22] 8371 (PD-1/PD-L1 Bispecific Antibody) - **Current Status**: Completed phase one dose escalation with no dose-limiting toxicities [5][6] - **Response Rate**: Three confirmed responses in 15 patients treated, including significant tumor reduction in a triple-negative breast cancer patient [6][7] - **Next Steps**: Moving to cohort expansions for non-small cell lung cancer and triple-negative breast cancer, with potential for approval studies in 2026 [30][32] 10726 (PD-1/VEGF Bispecific Antibody) - **Current Status**: Expected IND filing and phase one initiation in the first half of 2026 [33] - **Target Indications**: Hepatocellular cancer, gastric cancer, renal cell cancer, and endometrial cell cancer [33] Market Potential - **Biliary Tract Cancer**: Approximately 25,000 new cases annually in the U.S., with an increasing incidence projected [24] - **Eligible Patients for Tevesemig**: Estimated 15,000 patients annually in the U.S. alone, significantly larger than the platinum-resistant ovarian cancer market [24][25] - **Global Market**: Over 100,000 patients diagnosed annually across the U.S., EU, and Japan [25] Regulatory and Commercialization Strategy - **BLA Submission Timeline**: Expected in the second half of 2026, following positive interactions with the FDA [23] - **Commercialization Plans**: Preparing to launch Tevesemig independently in the U.S., with potential partnerships for ex-U.S. markets [26] Statistical Analysis and Methodology - **Statistical Techniques**: Utilizing Rank Preserving Structural Failure Time (RPSFT) for OS analysis to account for crossover patients [16][17] - **Hierarchical Testing**: Employed to control alpha spending across multiple endpoints [20] Additional Insights - **Clinical Operations**: Low patient loss to follow-up (approximately 5%) indicates strong clinical management [13] - **Future Outlook**: 2026 is anticipated to be a pivotal year for Compass Therapeutics with multiple potential approvals and market entries [32][33]